
According to the CEO of an influential diabetes center in Copenhagen, Novo Nordisk has gained a worthy opponent within the diabetes indication in the form of Eli Lilly’s Mounjaro (tirzepatide), which was recently approved in the US.
Allan Flyvbjerg, CEO of Steno Diabetes Center, said the following to industry media Dagens Pharma:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app